L Palop

Publications (25)64.65 Total impact

• Article: Nocturnal ultrafiltration profiles in patients on APD: impact on fluid and solute transport.

  N D Vega, R Gallego, E Oliva, F Henriquez, L Palop, J C Divino Filho, B Lindholm
  [show abstract] [hide abstract]
  ABSTRACT: In order to prevent morbidity and mortality in peritoneal dialysis (PD), sodium and water balance as well as a minimal level of small-solute clearances are needed. The impact of three nocturnal peritoneal ultrafiltration (UF) profiles on UF and small solute clearance in patients on automated PD (APD) was studied: constant glucose concentration of 1.36% (flat) or modifying the glucose concentration of the heater bag (descendant: 3.86-1.36%; ascendant: 1.36-3.86%). Sixty-two patients were enrolled in the study and received each profile within a four-month period, thus serving as their own controls. UF was lower with the flat profile (367+/-420ml; P<0.01), but no difference was seen between the two higher glucose concentration profiles. Peritoneal Kt/V (pKt/V) and peritoneal creatinine clearance (CrpC) showed statistically higher values from the descendant vs ascendant vs flat profiles (pKt/V: 1.54+/-0.30 vs 1.45+/-0.30 vs 1.38+/-0.27, and CrpC: 36.9+/-7.9 vs 33.5+/-7.48 vs 29.92+/-7.5 mlmin(-1)). Multivariate analysis showed statistical significance for the following: in the intrasubject comparisons, the profile for pKt/V (F=9.109, P<0.001) and CrpC (F=11.697, P<0.001), and in the intersubjects comparisons, the effects of both gender (F=14.334, P<0.01) for pKt/V and peritoneal permeability for both parameters (pKt/V: F=4.37, P<0.05; CrpC: F=11.697, P<0.001). In conclusion, the application of ascendant and descendant UF profiles in automated PD is feasible and results in better UF and small solute clearances, thus preventing inadequate dialysis and volume overload..
  Kidney international. Supplement 05/2008;
• Article: Steroids and bone density in patients with functioning kidney allografts.

  R Gallego, E Oliva, N Vega, S Ojeda, L Hortal, F F Hernández, A Fernández, A Eisman, D Silva, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: Osteopenia and osteoporosis after renal transplantation have been associated with factors related to the cause of end-stage renal disease, as well as to clinical events and therapeutic factors in the posttransplant period. We studied the prevalence of low bone density (LBD) according to WHO criteria. A cross-sectional study was performed in a cohort of 106 patients (54 men and 52 women) with functioning renal allografts, who underwent bone densitometry (DEXA) of the lumbar spine and femoral neck. Patients were grouped according to DEXA into those with normal bone density (NBD) or LBD. We studied clinical, analytical, and therapeutic variables. Thirtysix patients (34%) had NBD and 70 patients (66%) LBD. Weight was the only parameter showing a significant difference (P = .034), namely, among NBD it was 80.44+/-15.13 versus LBD 73.94 +/- 14.54 kg, respectively. Creatinine clearance (CCr) tended to be lower among patients with LBD 59.62 +/- 22.73 versus 69.59 +/- 28.15 mL/min in patients with NBD (P = .052). PTHi levels were higher in patients with LBD (149.39 +/- 110.75) than those with NBD (110.94 +/- 82.61) (P = .069). In the multivariate analysis the important determinants were weight Exp(ss) = 0.967 [CI = 0.939 to 0.996] (P = .036); CCr Exp(ss) = 0.982 [CI = 0.965 to 1.000] (P = .055); and PTHi levels Exp(ss) = 1.003 [CI = 0.932 to 0.994] (P = .059). Osteopenia and osteoporosis are frequent among kidney transplant patients (66%), with a similar distribution between the lumbar spine and femoral neck. Excess weight and possibly better renal function may be protective factors. The cumulative steroid dose showed a significant effect on bone density. As expected, secondary hyperparathyroidism in patients with renal impairment seemed to be a risk factor for LBD.
  Transplantation Proceedings 11/2006; 38(8):2434-7. · 1.00 Impact Factor
• Source

  Available from: Miguel Fernandez-Burriel

  Article: [Molecular diagnosis of adult dominant polycystic kidney disease in the Canary Islands].

  M J Torres, J C Rodríguez Pérez, C R Hernández Socorro, A Anabitarte, A Caballero, C Vázquez, M Fernández-Burriel, P Pérez Borges, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: Adult dominant polycystic kidney disease is an hereditary condition responsible for 6% of end-stage renal failure in Spain. Two genes were located in chromosomes 16 and 4 as related to this age-dependent disease in the 90s (PKD1 and PKD2). The diagnosis can be easily achieved by sonographic study, but molecular analysis by means of linkage analysis has the advantage of an early diagnosis in asymptomatic genetic carriers, with a view to the preventive follow-up of these subjects and genetic counselling. In this paper we present the results of molecular analysis of 30 families with Adult Dominant Polycystic Kidney Disease (from the province of Las Palmas Spain), carried out linkage analysis with two series of microsatellite markers located within or in the vicinity ofPKD1 (D16S521, KG8, AC2.5, CW2, SM7) and PKD2 (D4S1538, D4S1534, D4S423,D4S414) genes. The objectives of the study were: first, to verify the informativeness, and therefore, the usefulness of these markers for family studies in our population; and second,to assess the sensitivity and specificity of the genetic analysis in our population. Most of the markers showed a high heterozygosity, comparable to data in other studies. Considering the alleles of the different markers together in a chromosome as an haplotype increased the informativeness of the markers, and allowed the unequivocal identification of genetic data in 97.7% of patients and 88.7% of healthy subjects. The sensitivity and specificity of the genetic analysis were 90.7% (CI 95%: 85.7-95.7) and 86.8% (CI 95%: 80.6-93.0), respectively.
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2006; 26(6):666-72. · 1.00 Impact Factor
• Article: [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].

  J C Rodríguez Pérez, J Novoa Novoa, A Caballero, A Anabitarte, C Plaza, L Palop, F Rodríguez Esparragón
  [show abstract] [hide abstract]
  ABSTRACT: Arterial hypertension and diabetes mellitus give rise to a situation of high cardiovascular risk. The potential renoprotection from inhibition of the renin-angiotensin system is a valid option in this type of patient. Evaluate the effect of valsartan on blood pressure (BP) and renal function in albuminuric patients with type 2 diabetes and arterial hypertension. This was a prospective, observational study. Seventy-four diabetic patients with a blood pressure of > or = 140/90 mmHg, with micro or macroalbuminuria and a) blood creatinine levels lower 1.5 mg/dl (group 1) or b) blood creatinine levels between 1.5 and 2 mg/dl (group 2), were studied and followed up for a 12-week period. Treatment was started with valsartan 80 mg/d, increasing to 160 mg/d, adding torasemide at a dose of 5 mg/d if the target blood pressure of 130/85 mmHg has not been achieved. The degree of BP reduction was analyzed comparatively using a mercury sphygmomanometer and a semi-automatic monitor, the Omron HEM 705 CP. All patients showed a significant reduction of the systolic (SBP) and diastolic (DBP) blood pressures (p< 0.001) over the study period, decreasing from 150.7 +/- 12.8 to 130.8 +/- 9.6 and from 94.7 +/- 7.7 to 76.8 +/- 6.3 mmHg, respectively. A significant reduction was observed only for diastolic blood pressure (101.4 +/- 8.8 to 79.4 +/- 5.6; p < 0.001) in the group 2 of patients. Lowest BP values were always obtained with the semiautomatic device. At the end of the study, 9.5% maintained valsartan 80 mg/d and 36.5% reqcuired the addition of a second or third drug to valsartan 160 mg in order to achieve the therapeutic target BP A significant reduction was observed in the microalbuminuria (75.5 +/- 9.5 to 54.7 +/- 7.3 microg/min; p < 0.001) and macroalbuminuria (n = 20; 0.93 +/- 0.4 to 0.68 +/- 0.4 g/day; p < 0.001). Valsartan significantly reduced SBP and DBP Valsartan at 160 mg/d had a significantly greater effect in reducing micro and macroalbuminuria. No changes were observed in renal function, HbA1c or serum potassium. The rate of adverse events was very low.
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 01/2005; 25(5):500-8. · 1.00 Impact Factor
• Article: [Renal protective therapy in diabetic nephropathy. Available evidence].

  J C Rodríguez Pérez, F J Rodríguez Esparragón, O Hernández Perera, C Plaza, L Palop
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2001; 21 Suppl 3:58-65. · 1.00 Impact Factor
• Article: [Epidemiologic study of infection by hepatitis C virus in a hemodialysis unit].

  M J Pena, L Molina, L Hortal, R Gallego, J L Rodríguez, M C Pérez, L Palop, M D Fiuza, B Lafarga
  [show abstract] [hide abstract]
  ABSTRACT: To analyze the prevalence of infection, the frequency of HCV genotypes and the epidemiology characteristics among the patients in hemodialysis treatment in one 25 years old hospital hemodialysis center and one 15 years old secondary unit by a transversal cross-section study in 1998. 171 hemodialyzed-patients were studied. Patients sera were analyzed by the presence of HCV antibodies anti-VHC by a enzymoimmunoassay (Abbott Cientifica) and the presence of antibodies was confirmed by a line immunoassay (Inno-LIA HCV AbIII) and by the presence of VHC-RNA by reverse transcriptase PCR (Cobas Amplicor HCV). Genotypes were determinate by reverse hybridization (Inno-LIA HCV III). Fifty (29.2%) of the patients were HCV antibody positive. Forty-five (26.3%) were HCV-RNA positive, all of them with antibodies positive. The distribution of genotypes was: 1b, 34 (75.5%); 4f, 4 (8.9%); 1a, 3 (6.7%); 1, 3 (6.7%) and 1 case could not be typed (2.2%). In 14 patients (28.0%), seroconversions were documented Twenty-one patients (42.0%) were diagnosed when the routine tests were available and 15 patients (30.0%) were diagnosed pre-dialysis. The multivariate analysis showed that the risk of HCV infection was greater for patients who had been more 8 years on dialysis (OR: 6.22; 95% CI: 1.24-31.07). Data presented indicate that the prevalence of HCV infections in our hemodialysis units and the number of seroconversions were high and the HCV subtype 1b was more frequent; because of this, the screening by both serological and molecular methods is necessary, at least twice a year, to identify all the infected patients. Besides, we think that is necessary to increase the control of the completion of the Universal Precautions.
  Enfermedades Infecciosas y Microbiología Clínica 01/2001; 18(10):496-9. · 1.49 Impact Factor
• Article: Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.

  L Hortal, A Fernández, N Vega, J C Rodríguez, A Losada, M Lorenzo, C Plaza, L Palop
  Transplantation Proceedings 09/1998; 30(5):2127-8. · 1.00 Impact Factor
• Article: Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats.

  J C Rodriguez-Perez, A Losada, A Anabitarte, J Cabrera, J Llobet, L Palop, C Plaza
  [show abstract] [hide abstract]
  ABSTRACT: Antihypertensive drugs have differing effects on renal hemodynamics and morphology. We analyzed whether the use of a new beta adrenoceptor antagonist and vasodilator, carvedilol (CVD), slows the progression of nephrosclerosis and whether the renoprotective effect as well as reduction in cardiac hypertrophy is dependent on the degree of blood pressure reduction. Fifty-four adult male Sprague-Dawley rats were distributed among five groups: group I served as untreated controls with 5/6 nephrectomy (Nx); group II, sham (no renal ablation or drug treatment); group III, CVD 5 (5/6 Nx and treatment with oral CVD at 5 mg/kg/day); group IV, CVD 10 (5/6 Nx and treatment with oral CVD at 10 mg/kg/day); and group V, CVD 20 (5/6 Nx and treatment with oral CVD at 20 mg/kg/day). Tail-cuff blood pressure and 24-hr urine samples were obtained before and at 3, 5 and 11 weeks of treatment with CVD. At the end of the study period, blood was taken to measure serum creatinine, plasma renin activity and CVD levels, as well as the remnant kidney and heart for morphological studies. There was a significant reduction in 24-hr U(ProtV) in all the CVD-treated groups, and it was increasingly evident with the highest dose used. However, only rats receiving doses of 10 and 20 mg/kg/day of CVD exhibited significant decreases in blood pressure. Elevated serum creatinine levels seen in untreated controls were significantly decreased by CVD in treated rats (P < .01), indicating that glomerular filtration rate was improved by this drug. This was associated with a significant increase in U(NaV). Concomitant and significant (P < .01) decreases in plasma renin activity were observed in sham and CVD-treated rats. CVD-treated animals had considerably reduced renal damage (P < .01) and cardiac hypertrophy (P < .01) compared with untreated controls. These data indicate that CVD is effective in delaying progression of renal damage and provides beneficial effects in the remnant kidney and cardiac hypertrophy, even at nonhypotensive doses.
  Journal of Pharmacology and Experimental Therapeutics 11/1997; 283(1):336-44. · 3.83 Impact Factor
• Source

  Available from: ajcn.org

  Article: Cross-sectional assessment of nutritional and immune status in renal patients undergoing continuous ambulatory peritoneal dialysis.

  L Palop, J A Martínez
  [show abstract] [hide abstract]
  ABSTRACT: Malnutrition prevalence and immunocompetence were assessed in uremic patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Forty-two males and twenty-four females with kidney disease treated with CAPD were distributed into three groups according to the length of time they had been undergoing dialysis. Group 0 included patients beginning dialysis; group 1, patients undergoing CAPD for < 30 mo; and group 2, patients undergoing CAPD for > 30 mo. Body weight and body mass index were greater in patients who had been undergoing CAPD for longer periods of time (approximately 11% in males and 14% in females), which was accompanied by higher fat stores and muscle mass when assessed through triceps skinfold thickness and arm muscle measurements. These differences were more apparent in females than in males. Immunoglobulin M values were lower in patients in groups 1 and 2 than in group 0, whereas retinol binding protein, fibronectin, and C4 were higher. Estimated protein intake was higher in predialysis patients (1.31 g.d-1.kg-1) than in the other groups (approximately 0.95 g.d-1.kg-1). The percentage of B cells decreased with time on dialysis. Although no changes in total or helper T cells were found, a significant rise was noted for the T cell subpopulation with assumed suppressor and cytotoxic activities and for natural killer cells in those patients undergoing longer periods of CAPD treatment. Alterations in immune cell numbers in immunoglobulins and complement proteins might be responsible for immunologic disturbances and infectious processes occurring in patients with chronic renal failure and undergoing CAPD.
  American Journal of Clinical Nutrition 08/1997; 66(2):498S-503S. · 6.67 Impact Factor
• Article: Nutritional status of CAPD patients at three years.

  L Palop, N Vega, T Rodriguez, A Fernandez, J C Rodriguez, C Plaza, L Hortal, M Perdomo, E Baamonde, P Perez, J A Martinez
  [show abstract] [hide abstract]
  ABSTRACT: A nutritional assessment was carried out in 63 patients starting treatment from April 1990 up to December 1993. Anthropometric measurements were performed showing a prevalence of protein-calorie malnutrition (PCM) of 21% in a total of 142 clinical surveys carried out in the above-mentioned sample. A steady state of albumin levels in plasma was verified during a three-year follow-up period at a lower level than that of the control group. The patients' lymphocytic profile throughout the study was characterized by lymphopenia and decreased B and T8 lymphocytes. During the first two years of continuous ambulatory peritoneal dialysis (CAPD), a high percentage of patients met the "adequacy" dialysis criteria as residual renal function plays an important role as regards treatment.
  Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 02/1996; 16 Suppl 1:S195-202. · 2.10 Impact Factor
• Article: Lipoprotein (a) levels in patients undergoing continuous ambulatory peritoneal dialysis.

  C Guindeo, N Vega, A M Fernandez, L Palop, J A Aguilar, A Moreda, P Cia
  [show abstract] [hide abstract]
  ABSTRACT: Most researchers have found increases of lipoprotein (a) [Lp(a)] in uremic patients, as well as in those undergoing hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). The mechanisms for this increase remain unclear. We studied 71 patients undergoing CAPD, 48 men and 23 women. According to the time spent on CAPD, the patients were divided into three groups: group 0: 29 patients at the starting off point of dialysis treatment; group I: 22 patients with an average stay of 15.2 months; group II: 20 patients with an average stay of 69.3 months on CAPD. We have only observed significant increases of Lp(a) levels in those patients initiating the dialysis, but no significant differences are found in the other groups undergoing CAPD for longer periods when compared to the control group. We found no significant relation between Lp(a) levels and peritoneal protein loss, and not with absorption of glucose from the dialysate either. We have found a positive and significant correlation between Lp(a) levels and urinary protein loss (r = 0.41; p < 0.001). It is possible that an element associated with proteinuria might have an effect on the metabolism of Lp(a) in CAPD patients.
  Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 01/1996; 16 Suppl 1:S236-40. · 2.10 Impact Factor
• Source

  Available from: Manuel Macia

  Article: Percutaneous embolization of splenic artery pseudoaneurysm as a treatment of hemoperitoneum in a CAPD patient.

  M Macia, J M Pulido-Duque, L Hortal, N Vega, J Garcia-Medina, E Ortiz, M Maynar, L Palop
  Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 02/1993; 13(2):157-9. · 2.10 Impact Factor
• Source

  Available from: Manuel Macia

  Article: Neisseria mucosa peritonitis in CAPD: another case of the "nonpathogenic" Neisseriae infection.

  M Macia, N Vega, R Elcuaz, T Aterido, L Palop
  Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 02/1993; 13(1):72-3. · 2.10 Impact Factor
• Article: Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients.

  A Fernández, N Vega, F Jiménez, M Macía, E Laraudiogoitía, L Hortal, M Perdomo, C Plaza, J C Rodríguez, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: We studied the hemodynamic changes and the incidence of hypertension after correction of anemia with recombinant human erythropoietin (rhEPO) in 25 hemodialysis (HD) and in 27 continuous ambulatory peritoneal dialysis (CAPD) patients with a mean age of 44.6 years and a mean time on dialysis of 43.6 months. We analyzed basal and final hemoglobin concentrations, time elapsed to reach target hemoglobin, rhEPO dosage, and the following echocardiographic parameters: left ventricular end-systolic and end-diastolic diameters and volumes, posterior wall thickness, interventricular septum, ejection fraction, fractional fiber shortening, cardiac output index, and peripheral vascular resistance index. We did not find any significant difference between HD and CAPD patients in basal and final hemoglobin, concentrations, time elapsed to reach target hemoglobin, dose of rhEPO received for response, and incidence of hypertension. Changes were more evident in HD patients, with a decrease of 15% in cardiac output index and an equal increase of peripheral vascular resistance,. In the patients on CAPD, these variations were less important, with a decrease in cardiac output index of 10% and no significant change in peripheral vascular resistance. Despite both techniques showing the occurrence of hypertension, the left ventricular mass stabilized during the study time. We conclude that CAPD seems to modulate the changes observed in hemodynamic parameters after rhEPO treatment.
  American Journal of Nephrology 02/1992; 12(4):207-11. · 2.54 Impact Factor
• Article: Could CAPD modulate the hemodynamic changes induced by rHuEPO treatment?

  A Fernández, N Vega, L Hortal, F Jimenez, E Laraudogoitía, M Macía, C Plaza, M Perdomo, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: Hemodynamic response to treatment with erythropoietin has been analyzed on two different groups of patients. The first group of 25 patients was treated with hemodialysis. The second group of 27 was treated with peritoneal dialysis. Both groups were studied before starting the treatment with erythropoietin, after reaching the hemoglobin target point, and after one year of treatment. The following parameters were recorded: basal and hemoglobin target point, time and dosage of response, incidence of arterial hypertension, diastolic and systolic left ventricular diameters, interventricular septum and posterior wall thickness, ejection fraction, fractional fiber shortening, left ventricular mass index, cardiac output index and peripheral resistance index. The incidence of hypertension was 28.8% and, in both techniques, stabilization of left ventricular mass index occurred a year later. When the hemoglobin target point was reached, a decrease in cardiac output and an increase in peripheral resistance was found. These changes were more evident in the group of patients treated with HD. After a year of treatment, both peripheral resistance and cardiac output were similar to basal values in both groups of patients.
  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 02/1992; 8:435-9.
• Article: Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.

  N Vega, A Fernandez, L Hortal, M Macias, J C Rodriguez, C Plaza, M Perdomo, R Vega, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: Possible modifications in peritoneal behaviour that can be caused by erythropoietin (EPO) treatment and/or correction of anemia in the ultrafiltration and peritoneal diffusion were studied in 24 CAPD patients. The evolution of the patients on the medium run was also studied. The dialysate to plasma ratio, the peritoneal clearance and the mass transfer coefficient of urea and creatinine and the ultrafiltration volume were studied, baseline, after reaching the hemoglobin target, and after eight months of treatment. The group of patients developed a decrease in the dialysate to plasma ratio and in the peritoneal clearance of creatinine. After evaluating the effects of the hemoglobin and the hematocrit, we found a decrease in the dialysate to plasma ratio of urea and creatinine, and in the peritoneal clearance of creatinine. A decrease was also found in the mass transfer coefficients of urea and creatinine. An increase in the ultrafiltration was also found in the patients with hemoglobin levels higher or equal to 11 g/dl. Those changes are reversible after turning the hemoglobin levels back to levels lower than 11 g/dl.
  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 02/1992; 8:467-70.
• Article: Low turnover bone disease is the more common form of bone disease in CAPD patients.

  J C Rodriguez-Perez, C Plaza, A Torres, N Vega, A Anabitarte, A Fernandez, V Lorenzo, L Hortal, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: CAPD is considered a risk factor for low turnover bone disease. This was previously attributed to aluminum accumulation. We evaluated by biochemical and histomorphometric parameters (including double tetracycline labelling), 26 patients maintained on CAPD for 12-14 months. Three (11.5%) showed mild hyperparathyroidism, 5 (19.2%) osteitis fibrosa, 3 (11.5%) mixed forms, 4 (15%) osteomalacia and 11 (42.3%) adynamic bone disease. Only one patient with diabetes mellitus showed an aluminum stained bone surface > 10%. Intact PTH serum levels were lower in LTBD (133.2 +/- 128 vs 468.2 +/- 451 pg/ml; p < 0.05). We also evaluated prospectively 11 patients who underwent a bone biopsy at start of dialysis and after 12 months of CAPD treatment. Bone biopsies pre CAPD demonstrated normal-high bone turnover disease in 8/11 (72.7%) and low turnover bone disease in 3/11 (27%). In the follow-up biopsies, 2 patients showed osteitis fibrosa and other two mild forms. Low turnover bone disease was found in 7 patients (3 osteomalacia and 4 adynamic bone disease). We conclude that the predominant bone lesion in our CAPD patients is low turnover bone disease, predominantly adynamic forms, and aluminum does not seem to play a role on its genesis. Low intact PTH serum levels may be a predictor of low turnover bone disease.
  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 01/1992; 8:376-80.
• Article: Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin.

  A Férnandez, L Hortal, J C Rodríguez, N Vega, C Plaza, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: Acquired cystic kidney disease has been related to improvement of anemia in dialysis patients. It has been suggested that this could be due to erythropoietin production by the cysts. We studied 110 patients, 58 on hemodialysis and 52 on continuous ambulatory peritoneal dialysis, with an age of 48.6 +/- 14.78 years and a time on dialysis of 44.5 +/- 35.53 months. A renal echography was performed in every patient, evaluating presence and number of cysts. These findings were related to the blood levels of hemoglobin, ferritin, and erythropoietin as well as to the number of transfusions prescribed during the year of the study. The serum erythropoietin level was 18.23 +/- 12.14 U/l in hemodialysis patients, 15.04 +/- 12.35 in patients on continuous ambulatory peritoneal dialysis, and 12.4 +/- 4.7 U/l in the control group. Hemoglobin and erythropoietin were significantly higher in patients with polycystic kidney disease. Patients without cysts had the lowest levels of hemoglobin and erythropoietin, although no significant difference was found in those with multiple bilateral cysts or in those with 1-3 isolated cysts.
  American Journal of Nephrology 02/1991; 11(1):12-5. · 2.54 Impact Factor
• Article: Arterial calcification in diabetic patients undergoing CAPD.

  J C Rodríguez-Pérez, N Vega, A Torres, C Plaza, V Lorenzo, A Fernández, L Hortal, L Palop
  Contributions to nephrology 02/1991; 89:205-13. · 1.49 Impact Factor
• Article: Percutaneous transluminal angioplasty as best treatment in stenosis of vascular access for hemodialysis.

  J C Rodriguez-Perez, M Maynar, A Rams, C Plaza, N Vega, R Alamo, R Reyes, A Fernandez, L Palop
  [show abstract] [hide abstract]
  ABSTRACT: We show the results of treatment with percutaneous transluminal angioplasty on 38 occasions for vascular access for hemodialysis. Our study includes 22 patients with A-V internal fistulas (Cimino type), 1 autologous saphenous vein shunt and 7 synthetic polytetrafluoro-ethylene shunts. Twenty patients have had a follow-up period over 24 months. Four patients required a second and 2 of them a third transluminal dilatation. Only on two occasions were complications related to the technique. The microscopic findings of the venous wall after percutaneous transluminal angioplasty are shown.
  Nephron 02/1989; 51(2):192-6. · 13.26 Impact Factor